Failure of benefit and early hazard of bucindolol for Class IV heart failure

Journal of Cardiac Failure

Volumn 9, Issue 4, 2003, Pages 266-277

  Anderson, Jeffrey L ^a,l   Krause Steinrauf, Heidi ^b   Goldman, Steven ^c   Clemson, Barry S ^d   Domanski, Michael J ^b   Hager, W David ^e   Murray, David R ^f   Mann, Douglas L ^g   Massie, Barry M ^h   McNamara, Dennis M ⁱ   Oren, Ron ^j   Rogers, William J ^k  

^a UNIVERSITY OF UTAH   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

^d HeartCare Midwest   (United States)

^e UNIVERSITY OF CONNECTICUT   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

^h SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF PITTSBURGH   (United States)

^j UNIVERSITY OF IOWA   (United States)

^k UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^l UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Bucindolol; Heart failure; Survival; blocker

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; NORADRENALIN; PLACEBO;

ADULT; AGED; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; HEART EJECTION FRACTION; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SURVIVAL;

EID: 10744223608     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1054/jcaf.2003.42     Document Type: Article

References (29)

1. Massie MV, Shah NB. Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am Heart J 1997;133:703-12.
2. Heart Failure Society of America. Heart Failure Society of America practice guidelines: HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction: pharmacological approaches. J Cardiac Failure 1999;5:357-82.
3. Bristow MR. Beta-adrenergic receptor blockade in chronic heart failure. Circulation 2000;101:558-69.
4. Waagstein F, Hjalmarson A, Varnaysclas E, Wallentin I. Effect of chronic β-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975;37:1022-36.
5. Swedberg K, Waagstein F, Hjalmarson A, Wallentin I. Prolongation of survival in congestive cardiomyopathy by β-receptor blockade. Lancet 1979;I:1374-6.
6. Anderson JL, Lutz JR, Gilbert EM, Sorensen SG, Yanowitz FG, Menlove RL, et al. A randomized trial of low-dose β-blockade therapy for idiopathic dilated cardiomyopathy. Am J Cardiol 1985;55:471-5.
7. Engelmeier RS, O'Connell JB, Walsh R, Rad N, Scanlon P J, Gunnar RM. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation 1985;72:536-46.
8. Gilbert EM, Anderson JL, Deitchman D, Yanowitz FG, O'Connell JB, Renlund DG, et al. Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am J Med 1990;88:223-9.
9. Anderson JL, Gilbert EM, O'Connell JB, Renlund DG, Yanowitz FG, Murry M, et al. Long-term (2 year) beneficial effects of beta-adrenergic blockade with bucindolol in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1991;17:1373-81.
10. Waagstein F, Bristow MR, Swedberg K, Camerimi F, Fowler MB, Silver MA, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 1993;342:1441-6.
11. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al., for the U.S. Carvedilol Heart Failure Study Group. Effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
12. CIBIS-II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
13. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999;353:2001-7.
14. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A, for the V-HeFT VA Cooperative Studies Group. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. Circulation 1993;353:2001-7.
15. Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 1995;26:1257-63.
16. Ikram H, Chan W, Bennett SI, Bones PJ. Hemodynamic effects of acute β-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1979;42:311-5.
17. Hall SA, Cigarroa CG, Marcoux L, Riser RC, Grayburn PA, Eichhorn EJ. Time course of improvement in left ventricular function, mass, and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol 1995;25:1154-61.
18. The BEST Steering Committee. Design of the Beta-Blocker Evaluation of Survival Trial (BEST). Am J Cardiol 1995;75:1220-3.
19. The Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344: 1659-67.
20. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-33.
21. Gottlieb SS, Fisher ML, Kjekshus J, Deedwania PC, Gullestad L, for the MERIT-HF Investigators. Beta-blocker titration in MERIT-HF: safety and side effects. [abstract] Circulation 2000;102:II-628.
22. Packer M, Coats AJS, Fowler MB, Katus HA, Krum H, Moha P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-58.
23. Hershberger RE, Wynn JR, Sundberg L, Bristow MR. Mechanism of action of bucindolol in human ventricular myocardium. J Cardiovasc Pharmacol 1990;15:959-67.
24. Gilbert EM, Abraham WT, Olsen S, Hattler B, White M, Healy P, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996;94:2817-25.
25. Sederberg J, Wichman SE, Lindenfeld J, Wolfel E, Lowes B, Shakar S, et al. Bucindolol has no intrinsic sympathomimetic activity (ISA) in nonfailing human ventricular preparations. J Am Coll Cardiol 2000;35:207A.
26. Brixius K, Bundkirchen A, Boelck B, Mehlhorn U, Schwinger RHG. Lack of intrinsic Sympathomimetic activity of nebivolol, bucindolol, metoprolol, and carvedilol in human myocardium. [abstract] Circulation 2000;102:II-778.
27. The Xamoterol in Severe Heart Failure Study Group. Xamoterol in Severe Heart Failure. Lancet 1990;336:1-6.
28. Eichhorn EJ, Domanski MJ, Adams K, Bristow MR, Carson P, Yancy CW, et al. Hemodynamic, myocardial functional and neurohormonal responses to beta-blockade in black versus non-black patients in BEST. [abstract] Circulation 2000;102:II-778.
29. van Veldhuisen DJ, Poole-Wilson PA. The underreporting of results and possible mechanisms of 'negative' drug trials in patients with chronic heart failure. Int J Cardiol 2001;1:19-27.